Canakinumab (Ilaris)

medication bottles with pills

Canakinumab (Ilaris) is an interleukin-1β (IL-1β) blocker, which works to suppress the production of an inflammatory protein in the body. IL-1β is a pro-inflammatory protein released in states of infection and inflammation. Overproduction of IL-1β creates inflammation in the body resulting in symptoms such as fever, joint pain, and rashes. Canakinumab is a human monoclonal antibody which binds to the IL-1β protein and prevents it from attaching to its cellular receptor. As a result, canakinumab stops the inflammatory response commonly seen in autoinflammatory disorders, such as in systemic juvenile idiopathic arthritis.

Canakinumab is approved by the FDA for the treatment of Cryopyrin-associated periodic syndromes (CAPS, including Familial Cold Autoinflammatory Syndrome, Muckle-Wells, and Neonatal Onset Multisystem Inflammatory Disease (NOMID)), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD), Familial Mediterranean Fever (FMF), and Systemic Juvenile Idiopathic Arthritis (SJIA).

How to Take It

Canakinumab is a subcutaneous injection. Dosing schedules differ based on the disease, as listed as follows.

Cryopyrin Associated Periodic Syndrome

  • Body weight greater than or equal to 15 kg and less than or equal to 40 kg: The starting dose is 2 mg/kg administered subcutaneously every 8 weeks.
  • Body weight greater than 40 kg: The starting dose is 150 mg every 8 weeks.
  • For those with an inadequate response, the dose or frequency can be increased.

Tumor Necrosis Factor Receptor Associated Periodic Syndrome
Familial Mediterranean Fever (FMF)
Hyperimmunoglobulin D Syndrome (HIDS) / Mevalonate kinase deficiency (MKD)

  • Body weight less than or equal to 40 kg: The starting dose is 2 mg/kg administered subcutaneously every 4 weeks. The dose can be increased to 4 mg/kg every 4 weeks if the clinical response is not adequate.
  • Body weight greater than 40 kg: The starting dose is 150 mg every 4 weeks. The dose can be increased to 300 mg every 4 weeks, if the clinical response is not adequate.

Systemic Juvenile Idiopathic Arthritis (SJIA)

  • The dose is 4mg/kg every 4 weeks, up to a maximum dose of 300 mg per dose.

Side Effects

A documented allergy to canakinumab is an absolute contraindication to the drug. Side effects include cold and flue symptoms such as sore throat, runny nose, body aches, and cough, nausea, headache, and vertigo. Injection site reactions are the most common adverse event and have been reported in greater than 10% of patients treated with canakinumab.

Tell Your Rheumatology Provider

Since canakinumab suppresses your natural immune response, it can increase your risk of infection. Tell your rheumatology provider if you develop fevers or any signs or symptoms of infection. If you experience any allergic symptoms to canakinumab, you should immediately stop treatment and contact your doctor. Tell your doctor if you are pregnant or planning on conceiving soon. You shouold discuss updating your vaccinations prior to starting this medication as live vaccines should be avoided while taking canakinumab.

Updated February 2022 by Nina Washington, MD, and reviewed by the American College of Rheumatology Committee on Communications and Marketing.

This information is provided for general education only. Individuals should consult a qualified health care provider for professional medical advice, diagnosis and treatment of a medical or health condition.

© 2022 American College of Rheumatology.  All rights reserved.  Website & Privacy Policies | Sitemap | Help | Contact Us